RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
-16.57%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$2.32B
AUM Growth
+$2.32B
(-12%)
Cap. Flow
+$281M
Cap. Flow
% of AUM
12.09%
Top 10 Holdings %
Top 10 Hldgs %
50.61%
Holding
68
New
7
Increased
38
Reduced
3
Closed
3
Top Buys
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$36.8M |
| 2 |
OYST
Oyster Point Pharma, Inc. Common Stock
OYST
|
$33.9M |
| 3 |
Tandem Diabetes Care
TNDM
|
$28.6M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$26.1M |
| 5 |
Natera
NTRA
|
$25.8M |
Top Sells
| 1 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$44.1M |
| 2 |
Arvinas
ARVN
|
$13.1M |
| 3 |
Agilent Technologies
A
|
$12.8M |
| 4 |
Insulet
PODD
|
$11.6M |
| 5 |
Sarepta Therapeutics
SRPT
|
$7.48M |
Sector Composition
| 1 | Healthcare | 94.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $235M | 10.1% | 16,812,491 | – | – |
|
2
Alnylam Pharmaceuticals
ALNY
$58.5B
| $183M | 7.88% | 1,681,645 +43,781 | +3% | +$4.77M |
|
3
PTC Therapeutics
PTCT
$3.92B
| $175M | 7.55% | 3,932,746 +100,266 | +3% | +$4.47M |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $128M | 5.51% | 6,963,135 +1,088,906 | +19% | +$20M |
|
5
Bristol-Myers Squibb
BMY
$96B
| $94M | 4.05% | 1,685,934 +42,983 | +3% | +$2.4M |
|
6
Stoke Therapeutics
STOK
$1.08B
| $81.2M | 3.49% | 3,544,248 | – | – |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $75.7M | 3.26% | 985,166 +339,739 | +53% | +$26.1M |
|
8
Q32 Bio
QTTB
$20.9M
| $68.4M | 2.94% | 4,399,250 +50,000 | +1% | +$777K |
|
9
Zimmer Biomet
ZBH
$21B
| $67.9M | 2.92% | 671,457 +234,072 | +54% | +$23.7M |
|
10
Masimo
MASI
$7.59B
| $67.8M | 2.92% | 382,915 +728 | +0.2% | +$129K |
|
11
Immunovant
IMVT
$2.56B
| $65.9M | 2.84% | 4,426,106 | – | – |
|
12
Adverum Biotechnologies
ADVM
$64.6M
| $64.8M | 2.79% | 6,631,627 +245,020 | +4% | +$2.39M |
|
13
Axsome Therapeutics
AXSM
$6.05B
| $61.9M | 2.67% | 1,052,969 +26,156 | +3% | +$1.54M |
|
|
BLU
14
DELISTED
BELLUS Health Inc.
BLU
| $54.7M | 2.36% | 5,490,992 +650,000 | +13% | +$6.48M |
|
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $51.8M | 2.23% | 529,261 -76,501 | -13% | -$7.48M |
|
|
AXNX
16
DELISTED
Axonics, Inc. Common Stock
AXNX
| $43.4M | 1.87% | 1,709,000 +117,368 | +7% | +$2.98M |
|
17
Vericel Corp
VCEL
$1.83B
| $40.9M | 1.76% | 4,460,755 +1,471,326 | +49% | +$13.5M |
|
|
18
Natera
NTRA
$23.1B
| $37.8M | 1.63% | 1,266,125 +863,172 | +214% | +$25.8M |
|
19
Korro Bio
KRRO
$217M
| $36.9M | 1.59% | 2,071,199 +768,337 | +59% | +$13.7M |
|
|
TBIO
20
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $36.8M | 1.58% | 3,692,424 +387,616 | +12% | +$3.86M |
|
|
GBT
21
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $36.8M | 1.58% | +719,489 | New | +$36.8M |
|
|
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $36.6M | 1.58% | 780,898 +19,910 | +3% | +$933K |
|
|
AVDL
23
Avadel Pharmaceuticals
AVDL
$1.43B
| $36.3M | 1.56% | 4,616,570 +1,215,136 | +36% | +$9.54M |
|
|
OYST
24
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $33.9M | 1.46% | +969,478 | New | +$33.9M |
|
25
Relmada Therapeutics
RLMD
$37.2M
| $33.6M | 1.45% | 984,542 +320,058 | +48% | +$10.9M |
|